GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Pre-Tax Income
Switch to:

Biogen (BUE:BIIB) Pre-Tax Income

: ARS531,087 Mil (TTM As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. Biogen's pretax income for the three months ended in Mar. 2023 was ARS86,586 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2023 was ARS531,087 Mil. Biogen's pretax margin was 17.80%.

During the past 13 years, Biogen's highest Pretax Margin was 49.56%. The lowest was 15.89%. And the median was 41.23%.


Biogen Pre-Tax Income Historical Data

The historical data trend for Biogen's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Pre-Tax Income
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 222,444.43 425,940.70 410,765.54 176,247.74 602,165.25

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Pre-Tax Income Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37,301.05 152,758.94 190,514.34 101,227.07 86,586.17

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Pre-Tax Income Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Biogen's Pre-Tax Income falls in comparison to its industry or sector. The grey bar indicates the Pre-Tax Income's extreme value range as defined by GuruFocus.



Biogen Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Biogen's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=486503.522+142033.076+-41342.489+14971.145+-0.00099999993108213
=602,165

Biogen's Pretax Income for the quarter that ended in Mar. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=102192.617+-19241.37+-12346.875+15981.795+0
=86,586

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS531,087 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (BUE:BIIB) Pre-Tax Income Explanation

Biogen's Pretax Margin for the quarter that ended in Mar. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=86586.167/486565.661
=17.80%

During the past 13 years, Biogen's highest Pretax Margin was 49.56%. The lowest was 15.89%. And the median was 41.23%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Biogen's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines

From GuruFocus